Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study.


Journal

Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R

Informations de publication

Date de publication:
07 03 2020
Historique:
received: 24 07 2019
revised: 12 08 2019
accepted: 14 08 2019
pubmed: 8 9 2019
medline: 19 3 2020
entrez: 8 9 2019
Statut: ppublish

Résumé

To our knowledge, no previous study has prospectively documented the incidence of common diseases and related mortality in high-income countries (HICs), middle-income countries (MICs), and low-income countries (LICs) with standardised approaches. Such information is key to developing global and context-specific health strategies. In our analysis of the Prospective Urban Rural Epidemiology (PURE) study, we aimed to evaluate differences in the incidence of common diseases, related hospital admissions, and related mortality in a large contemporary cohort of adults from 21 HICs, MICs, and LICs across five continents by use of standardised approaches. The PURE study is a prospective, population-based cohort study of individuals aged 35-70 years who have been enrolled from 21 countries across five continents. The key outcomes were the incidence of fatal and non-fatal cardiovascular diseases, cancers, injuries, respiratory diseases, and hospital admissions, and we calculated the age-standardised and sex-standardised incidence of these events per 1000 person-years. This analysis assesses the incidence of events in 162 534 participants who were enrolled in the first two phases of the PURE core study, between Jan 6, 2005, and Dec 4, 2016, and who were assessed for a median of 9·5 years (IQR 8·5-10·9). During follow-up, 11 307 (7·0%) participants died, 9329 (5·7%) participants had cardiovascular disease, 5151 (3·2%) participants had a cancer, 4386 (2·7%) participants had injuries requiring hospital admission, 2911 (1·8%) participants had pneumonia, and 1830 (1·1%) participants had chronic obstructive pulmonary disease (COPD). Cardiovascular disease occurred more often in LICs (7·1 cases per 1000 person-years) and in MICs (6·8 cases per 1000 person-years) than in HICs (4·3 cases per 1000 person-years). However, incident cancers, injuries, COPD, and pneumonia were most common in HICs and least common in LICs. Overall mortality rates in LICs (13·3 deaths per 1000 person-years) were double those in MICs (6·9 deaths per 1000 person-years) and four times higher than in HICs (3·4 deaths per 1000 person-years). This pattern of the highest mortality in LICs and the lowest in HICs was observed for all causes of death except cancer, where mortality was similar across country income levels. Cardiovascular disease was the most common cause of deaths overall (40%) but accounted for only 23% of deaths in HICs (vs 41% in MICs and 43% in LICs), despite more cardiovascular disease risk factors (as judged by INTERHEART risk scores) in HICs and the fewest such risk factors in LICs. The ratio of deaths from cardiovascular disease to those from cancer was 0·4 in HICs, 1·3 in MICs, and 3·0 in LICs, and four upper-MICs (Argentina, Chile, Turkey, and Poland) showed ratios similar to the HICs. Rates of first hospital admission and cardiovascular disease medication use were lowest in LICs and highest in HICs. Among adults aged 35-70 years, cardiovascular disease is the major cause of mortality globally. However, in HICs and some upper-MICs, deaths from cancer are now more common than those from cardiovascular disease, indicating a transition in the predominant causes of deaths in middle-age. As cardiovascular disease decreases in many countries, mortality from cancer will probably become the leading cause of death. The high mortality in poorer countries is not related to risk factors, but it might be related to poorer access to health care. Full funding sources are listed at the end of the paper (see Acknowledgments).

Sections du résumé

BACKGROUND
To our knowledge, no previous study has prospectively documented the incidence of common diseases and related mortality in high-income countries (HICs), middle-income countries (MICs), and low-income countries (LICs) with standardised approaches. Such information is key to developing global and context-specific health strategies. In our analysis of the Prospective Urban Rural Epidemiology (PURE) study, we aimed to evaluate differences in the incidence of common diseases, related hospital admissions, and related mortality in a large contemporary cohort of adults from 21 HICs, MICs, and LICs across five continents by use of standardised approaches.
METHODS
The PURE study is a prospective, population-based cohort study of individuals aged 35-70 years who have been enrolled from 21 countries across five continents. The key outcomes were the incidence of fatal and non-fatal cardiovascular diseases, cancers, injuries, respiratory diseases, and hospital admissions, and we calculated the age-standardised and sex-standardised incidence of these events per 1000 person-years.
FINDINGS
This analysis assesses the incidence of events in 162 534 participants who were enrolled in the first two phases of the PURE core study, between Jan 6, 2005, and Dec 4, 2016, and who were assessed for a median of 9·5 years (IQR 8·5-10·9). During follow-up, 11 307 (7·0%) participants died, 9329 (5·7%) participants had cardiovascular disease, 5151 (3·2%) participants had a cancer, 4386 (2·7%) participants had injuries requiring hospital admission, 2911 (1·8%) participants had pneumonia, and 1830 (1·1%) participants had chronic obstructive pulmonary disease (COPD). Cardiovascular disease occurred more often in LICs (7·1 cases per 1000 person-years) and in MICs (6·8 cases per 1000 person-years) than in HICs (4·3 cases per 1000 person-years). However, incident cancers, injuries, COPD, and pneumonia were most common in HICs and least common in LICs. Overall mortality rates in LICs (13·3 deaths per 1000 person-years) were double those in MICs (6·9 deaths per 1000 person-years) and four times higher than in HICs (3·4 deaths per 1000 person-years). This pattern of the highest mortality in LICs and the lowest in HICs was observed for all causes of death except cancer, where mortality was similar across country income levels. Cardiovascular disease was the most common cause of deaths overall (40%) but accounted for only 23% of deaths in HICs (vs 41% in MICs and 43% in LICs), despite more cardiovascular disease risk factors (as judged by INTERHEART risk scores) in HICs and the fewest such risk factors in LICs. The ratio of deaths from cardiovascular disease to those from cancer was 0·4 in HICs, 1·3 in MICs, and 3·0 in LICs, and four upper-MICs (Argentina, Chile, Turkey, and Poland) showed ratios similar to the HICs. Rates of first hospital admission and cardiovascular disease medication use were lowest in LICs and highest in HICs.
INTERPRETATION
Among adults aged 35-70 years, cardiovascular disease is the major cause of mortality globally. However, in HICs and some upper-MICs, deaths from cancer are now more common than those from cardiovascular disease, indicating a transition in the predominant causes of deaths in middle-age. As cardiovascular disease decreases in many countries, mortality from cancer will probably become the leading cause of death. The high mortality in poorer countries is not related to risk factors, but it might be related to poorer access to health care.
FUNDING
Full funding sources are listed at the end of the paper (see Acknowledgments).

Identifiants

pubmed: 31492501
pii: S0140-6736(19)32007-0
doi: 10.1016/S0140-6736(19)32007-0
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

785-794

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Gilles R Dagenais (GR)

Department of Cardiology, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC, Canada.

Darryl P Leong (DP)

Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, ON, Canada.

Sumathy Rangarajan (S)

Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, ON, Canada.

Fernando Lanas (F)

Department of Medicine, Universidad de La Frontera, Temuco, Chile.

Patricio Lopez-Jaramillo (P)

Medical School, Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia.

Rajeev Gupta (R)

Eternal Heart Care Centre and Research Institute, Jaipur, India; Department of Medicine, Rajasthan University of Health Sciences, Jaipur, India.

Rafael Diaz (R)

Estudios Clinicos Latinoamérica, Rosario, Argentina.

Alvaro Avezum (A)

Department of Medicine, Hospital Alemão Oswaldo Cruz, Universidade de Santo Amaro, São Paulo, Brazil.

Gustavo B F Oliveira (GBF)

Dante Pazzanese Institute of Cardiology, São Paulo, Brazil.

Andreas Wielgosz (A)

Department of Medicine, University of Ottawa, Ottawa, ON, Canada.

Shameena R Parambath (SR)

Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, ON, Canada.

Prem Mony (P)

St John's Research Institute, St John's Medical College, Bangalore, India.

Khalid F Alhabib (KF)

Department of Cardiac Sciences, King Fahad Cardiac Centre, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Ahmet Temizhan (A)

Department of Cardiology, Faculty of Medicine, Saglik Bilimleri University, Ankara, Turkey.

Noorhassim Ismail (N)

Department of Community Health, Faculty of Medicine, University Kebangsaan Malaysia, Kuala Lumpur, Malaysia.

Jephat Chifamba (J)

Department of Physiology, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.

Karen Yeates (K)

Pamoja Tunaweza Women's Centre, Moshi, Tanzania; Division of Nephrology, Department of Medicine, Queen's University, Kingston, ON, Canada.

Rasha Khatib (R)

Institute for Community and Public Health, Birzeit University, Birzeit, Palestine; Advocate Research Institute, Advocate Health Care, Chicago, IL, USA.

Omar Rahman (O)

Independent University, Dhaka, Bangladesh.

Katarzyna Zatonska (K)

Department of Social Medicine, Wroclaw Medical University, Wroclaw, Poland.

Khawar Kazmi (K)

Department of Medicine, Aga Khan University, Karachi, Pakistan.

Li Wei (L)

National Centre for Cardiovascular Diseases, Cardiovascular Institute, Beijing, China; Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.

Jun Zhu (J)

Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.

Annika Rosengren (A)

Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden.

K Vijayakumar (K)

Health Action by People, Trivandrum, India; Amrita Institute of Medical Sciences, Kochi, India.

Manmeet Kaur (M)

School of Public Health, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Viswanathan Mohan (V)

Madras Diabetes Research Foundation, Chennai, India; Dr Mohan's Diabetes Specialities Centre, Chennai, India.

AfzalHussein Yusufali (A)

Department of Medicine, Hatta Hospital, Dubai Medical University, Dubai Health Authority, Dubai, United Arab Emirates.

Roya Kelishadi (R)

Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

Koon K Teo (KK)

Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, ON, Canada.

Philip Joseph (P)

Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, ON, Canada.

Salim Yusuf (S)

Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, ON, Canada. Electronic address: salim.yusuf@phri.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH